Duodenal ulcer Medical Services in China

A duodenal ulcer is a circumscribed mucosal defect in the first part of the duodenum—the initial segment of the small intestine—extending through the muscularis mucosae into the submucosa. It is a common form of peptic ulcer disease (PUD), distinguished from gastric ulcers by its anatomical location distal to the gastroduodenal junction. Pathogenesis centers on an imbalance between aggressive luminal factors (primarily gastric acid and pepsin) and defensive mucosal mechanisms. The overwhelming majority of cases (>90%) are associated with Helicobacter pylori infection, a gram-negative bacterium that colonizes the gastric antrum and induces chronic active gastritis, disrupts mucosal barrier integrity, and stimulates acid hypersecretion via cytokine-mediated pathways. Nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose aspirin, independently impair prostaglandin synthesis—critical for mucus and bicarbonate secretion and mucosal blood flow—thereby increasing ulcer risk even in H. pylori-negative individuals. Less common contributors include Zollinger-Ellison syndrome (gastrin-secreting tumors), smoking, severe physiological stress (e.g., major trauma or critical illness), and genetic predisposition (e.g., polymorphisms in IL-1β and TNF-α genes). Epidemiologically, duodenal ulcers affect approximately 5–10% of the global population over a lifetime, with higher prevalence in developing regions due to widespread H. pylori carriage. Incidence peaks between ages 30 and 50, and males are affected 2–3 times more frequently than females. While overall incidence has declined in high-income countries following H. pylori eradication campaigns and NSAID stewardship, it remains prevalent in China, where H. pylori seroprevalence exceeds 50% in adults and regional antibiotic resistance patterns complicate treatment. Key modifiable risk factors include untreated H. pylori infection, regular NSAID or corticosteroid use, cigarette smoking (which delays healing and doubles recurrence risk), excessive alcohol consumption, and chronic psychological stress—though stress alone does not cause ulcers. Untreated or recurrent ulcers significantly impair quality of life: patients commonly report nocturnal epigastric burning or gnawing pain relieved by food or antacids, postprandial discomfort, nausea, early satiety, and hematemesis or melena in complicated cases. Chronic symptoms lead to sleep disruption, reduced work productivity, dietary restrictions, anxiety about bleeding or perforation, and avoidance of social meals—contributing to measurable declines in physical functioning, vitality, and mental health domains on validated QoL instruments like the SF-36. With timely diagnosis—including upper endoscopy (gold standard) and rapid urease testing or stool antigen assays for H. pylori—and evidence-based therapy, most patients achieve complete mucosal healing and sustained remission.

Duodenal ulcers are discrete mucosal defects in the duodenal bulb, extending through the muscularis mucosae into the submucosa or deeper layers. They represent a common manifestation of peptic ulcer disease (PUD), with an estimated lifetime prevalence of 5–10% in Western populations. The pathogenesis involves an imbalance between aggressive luminal factors and mucosal defense mechanisms—primarily driven by Helicobacter pylori infection and nonsteroidal anti-inflammatory drug (NSAID) use, though these account for distinct pathophysiological subsets.

The most prevalent cause is chronic Helicobacter pylori infection, present in >90% of duodenal ulcer cases in endemic regions and approximately 70–80% globally. H. pylori colonizes the gastric antrum and induces localized inflammation, disrupting normal gastrin regulation and causing hypergastrinemia. This leads to increased acid secretion from parietal cells, particularly in the duodenal bulb where ectopic gastric metaplasia may permit bacterial colonization and direct mucosal injury. The organism’s urease activity, vacuolating cytotoxin (VacA), and cytotoxin-associated gene A (CagA) protein contribute to epithelial apoptosis, impaired bicarbonate secretion, and neutrophil infiltration—cumulatively eroding mucosal integrity.

NSAID use is the second leading cause, responsible for ~15–20% of duodenal ulcers, especially in older adults and those on long-term or high-dose regimens. NSAIDs inhibit cyclooxygenase-1 (COX-1), reducing prostaglandin E2 synthesis, which normally maintains mucosal blood flow, mucus/bicarbonate secretion, and epithelial restitution. Concurrent use of selective COX-2 inhibitors with low-dose aspirin or corticosteroids further amplifies risk. Importantly, NSAID-induced ulcers often occur without preceding H. pylori infection and may be more prone to complications such as bleeding or perforation.

Other notable triggers include physiological stressors: severe systemic illness (e.g., major trauma, burns, sepsis, mechanical ventilation), which can induce stress-related mucosal damage via splanchnic hypoperfusion, oxidative stress, and impaired mucosal repair. While classic 'Cushing ulcers' are gastric, duodenal involvement occurs in up to 25% of critically ill patients with stress ulceration. Smoking is a well-established modifiable trigger—nicotine increases gastric acid output, reduces duodenal bicarbonate secretion, impairs mucosal blood flow, and delays ulcer healing. Alcohol consumption, while not directly ulcerogenic at moderate levels, exacerbates mucosal injury when combined with H. pylori or NSAIDs and may promote reflux of gastric contents into the duodenum.

Genetic factors confer modest but significant susceptibility. Polymorphisms in interleukin-1β (IL-1B) and tumor necrosis factor-α (TNF-α) genes are associated with enhanced proinflammatory responses to H. pylori, increasing ulcer risk two- to threefold. Variants in the TLR4 gene (involved in bacterial lipopolysaccharide recognition) and FCGR2A (affecting immune complex clearance) also modulate host response. Familial aggregation is observed, with first-degree relatives of ulcer patients exhibiting 2–3× higher risk—partly attributable to shared H. pylori transmission patterns but also to inherited variations in acid secretion capacity (e.g., polymorphisms in the H+/K+ ATPase subunit genes) and mucosal barrier function.

Environmental determinants play a critical role. Socioeconomic status correlates inversely with duodenal ulcer incidence; overcrowding, poor sanitation, and limited access to clean water facilitate early-life H. pylori acquisition—particularly strains carrying the cag pathogenicity island. Urban-rural disparities persist, with higher prevalence in developing nations due to delayed diagnosis and treatment access. Occupational stress, while not causative per se, may potentiate ulcer recurrence via hypothalamic-pituitary-adrenal axis activation, elevated catecholamines, and reduced vagal tone—altering gastric motility and mucosal perfusion. Dietary factors remain controversial; spicy foods, caffeine, and acidic beverages do not initiate ulcers but may provoke dyspeptic symptoms and delay healing in active disease. Conversely, diets rich in fruits, vegetables, and fiber appear protective, possibly via antioxidant effects and modulation of gut microbiota.

Emerging evidence implicates other contributors: chronic use of bisphosphonates (especially oral formulations), serotonin reuptake inhibitors (SSRIs), and anticoagulants (e.g., warfarin, DOACs) may increase ulcer risk indirectly through mucosal irritation or impaired hemostasis. Zollinger-Ellison syndrome—a rare gastrin-secreting neuroendocrine tumor—accounts for <1% of duodenal ulcers but must be considered in refractory, recurrent, or atypical cases (e.g., multiple ulcers, distal duodenal or jejunal location, hypercalcemia, or diarrhea). In summary, duodenal ulcerogenesis reflects a multifactorial interplay of infectious, pharmacologic, genetic, behavioral, and environmental influences, necessitating comprehensive evaluation beyond symptom-directed management.

Duodenal ulcer, a common peptic ulcer disease entity, is characterized by a mucosal defect extending through the muscularis mucosae into the submucosa of the duodenal bulb—most frequently within 3 cm of the pylorus. It predominantly affects adults aged 30–55 years and exhibits a male predominance (2:1 ratio). Etiopathogenesis centers on an imbalance between aggressive luminal factors (primarily gastric acid and pepsin) and mucosal defense mechanisms, with Helicobacter pylori infection present in >90% of cases and NSAID use contributing significantly in non-H. pylori-related ulcers.

Early symptoms are often subtle and nonspecific, frequently overlooked or misattributed to functional dyspepsia. Patients may report intermittent epigastric discomfort described as a vague 'gnawing' or 'hollow' sensation, typically occurring 2–4 hours postprandially or during nocturnal fasting periods. This early discomfort may be transient, lasting minutes to an hour, and is often relieved by food intake or antacids—a hallmark feature reflecting acid-mediated symptom generation. Mild nausea, early satiety, or occasional belching may accompany these prodromal sensations. Importantly, up to 20% of patients remain asymptomatic until complications arise, underscoring the potential for silent progression.

Typical symptoms reflect localized ulcer activity and acid exposure. The cardinal manifestation is recurrent, well-localized epigastric pain—often described as burning, aching, or sharp—peaking in intensity 1–3 hours after meals and characteristically awakening the patient from sleep between midnight and 3 a.m. Pain relief following ingestion of food or alkaline agents (e.g., calcium carbonate) occurs in approximately 70–85% of cases due to buffering of gastric acid and reduced duodenal acid load. Pain duration varies from minutes to several hours; its cyclical nature—occurring in bouts over weeks or months with spontaneous remissions—is highly suggestive. Unlike gastric ulcers, duodenal ulcer pain rarely worsens with eating; instead, it commonly improves postprandially. Some patients develop a learned behavioral pattern of nocturnal snacking to preempt awakening pain.

Accompanying symptoms include heartburn (retrosternal burning), regurgitation, and mild nausea—though vomiting is uncommon unless complicated by obstruction. Anorexia may occur secondary to anticipatory pain, but significant weight loss is atypical and should prompt evaluation for malignancy or other systemic illness. Hematemesis or melena may appear even in the absence of overt pain, particularly in elderly or NSAID-exposed patients with diminished pain perception. Dyspeptic symptoms such as bloating and postprandial fullness are frequent but nonspecific. Notably, autonomic symptoms like diaphoresis or pallor are absent unless hemorrhage or perforation supervenes.

Complications represent critical clinical turning points. Upper gastrointestinal bleeding is the most common complication (occurring in ~25% of diagnosed cases), presenting as hematemesis (bright red or coffee-ground vomitus), melena (tarry, foul-smelling stools), or occult blood loss leading to iron-deficiency anemia (fatigue, exertional dyspnea, pallor). Perforation—less frequent (~5–10%) but life-threatening—manifests abruptly with severe, constant, knife-like epigastric pain radiating to the shoulders, abdominal rigidity, rebound tenderness, and signs of peritoneal irritation; free air on upright chest radiograph or CT confirms diagnosis. Gastric outlet obstruction (3–5% of cases) results from chronic inflammation, edema, or fibrotic scarring causing pyloric stenosis; symptoms include progressive postprandial vomiting (often voluminous and containing undigested food), early satiety, weight loss, and visible gastric peristalsis. Penetration—distinct from perforation—involves ulcer extension into adjacent structures (e.g., pancreas), causing persistent, deep, poorly localized pain unrelieved by standard therapy and potentially mimicking pancreatic or biliary pathology. Rarely, chronic ulcers undergo malignant transformation (<0.5%), though this remains exceedingly uncommon compared to gastric ulcers.

Diagnosis relies on a combination of clinical assessment and objective testing. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) remains the gold standard: it permits direct visualization of ulcer morphology (size, location, depth, stigmata of recent hemorrhage—Forrest classification), biopsy for H. pylori detection and histopathologic exclusion of malignancy, and therapeutic intervention (e.g., endoscopic hemostasis). In resource-limited settings or low-risk patients, non-invasive H. pylori testing (urea breath test, stool antigen assay, or serology—though latter lacks specificity for active infection) combined with empiric proton pump inhibitor (PPI) trial may be employed. Contrast-enhanced upper GI series demonstrates the classic 'niche' or 'crater' sign but lacks sensitivity for small ulcers and cannot assess for malignancy or guide biopsy. Laboratory evaluation includes complete blood count (to detect anemia), serum ferritin (for iron stores), and renal/hepatic function tests prior to PPI initiation.

Differential diagnosis must exclude entities with overlapping symptomatology. Functional dyspepsia presents with similar epigastric discomfort but lacks objective evidence of structural disease and shows no response to ulcer-healing therapy. Gastric ulcers cause pain that typically worsens with eating and lacks the pronounced nocturnal pattern; endoscopy is essential to distinguish location and rule out malignancy. Gastroesophageal reflux disease (GERD) features retrosternal burning, regurgitation, and positional exacerbation—notably absent epigastric nocturnal pain. Chronic pancreatitis may mimic penetrating duodenal ulcer with persistent mid-abdominal or back pain, but is associated with steatorrhea, diabetes, and imaging findings (calcifications, ductal dilation). Biliary colic presents with right upper quadrant or epigastric pain radiating to the scapula, often postprandial and associated with fatty meals, without acid-relief characteristics. Less common considerations include mesenteric ischemia (postprandial abdominal pain with weight loss), celiac disease (diarrhea, steatorrhea, anemia), and cardiac angina (exertional, radiation to arm/jaw, ST-T changes). Crucially, any new-onset dyspepsia in patients >55 years, with alarm features (weight loss, anemia, dysphagia, vomiting, family history of gastric cancer), mandates prompt endoscopic evaluation to exclude malignancy or other serious pathology.

Duodenal ulcers—circumscribed mucosal defects extending through the muscularis mucosae into the submucosa of the duodenal bulb—are predominantly caused by Helicobacter pylori infection (present in >90% of cases) and/or nonsteroidal anti-inflammatory drug (NSAID) use. Less common etiologies include hypersecretory states (e.g., Zollinger-Ellison syndrome), smoking, excessive alcohol intake, and physiological stress. Accurate diagnosis relies on upper gastrointestinal endoscopy with biopsy for H. pylori testing (rapid urease test, histology, or culture) and, when indicated, serum gastrin measurement. Conservative management forms the cornerstone of therapy, emphasizing ulcer healing, symptom relief, eradication of underlying causative factors, and prevention of recurrence and complications—including bleeding, perforation, and gastric outlet obstruction.

Conservative treatment begins with immediate lifestyle and behavioral modification. Patients are advised to discontinue NSAIDs unless absolutely necessary; if continued, co-therapy with a proton pump inhibitor (PPI) is mandatory. Smoking cessation is strongly emphasized, as nicotine impairs mucosal blood flow, delays ulcer healing, and increases recurrence risk by up to 2-fold. Alcohol consumption should be minimized or eliminated due to its direct mucosal irritant effect and synergistic interaction with acid secretion. Dietary adjustments focus on symptom-guided moderation rather than rigid restrictions; while spicy, acidic, or caffeinated foods do not cause ulcers, they may exacerbate dyspepsia in sensitive individuals and warrant individualized avoidance.

Pharmacotherapy is stratified into three interdependent pillars: acid suppression, H. pylori eradication, and mucosal protection. First-line acid suppression employs high-dose PPIs—such as esomeprazole 40 mg once daily, rabeprazole 20 mg twice daily, or pantoprazole 40 mg once daily—for 4–6 weeks. PPIs achieve intragastric pH >4 for >16 hours daily, optimizing conditions for epithelial restitution and reducing pepsin activity. In patients with documented H. pylori infection, standard triple therapy (PPI + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily for 14 days) remains effective where clarithromycin resistance is <15%. However, due to rising global resistance (>25% in many regions), bismuth quadruple therapy (PPI + bismuth subsalicylate 524 mg four times daily + tetracycline 500 mg four times daily + metronidazole 500 mg three or four times daily for 10–14 days) is increasingly recommended as first-line in high-resistance settings. All regimens require strict adherence and post-treatment confirmation of eradication via urea breath test, stool antigen test, or repeat endoscopy with biopsy at least 4 weeks after antibiotic completion and 2 weeks after PPI discontinuation. For NSAID-induced ulcers without H. pylori, long-term PPI maintenance (e.g., omeprazole 20 mg daily) is indicated if NSAID continuation is unavoidable. Sucralfate (1 g four times daily) may serve as adjunctive mucosal protectant in select cases, particularly where PPIs are contraindicated, though evidence for superiority over PPI monotherapy is lacking.

Surgical intervention is now rare—reserved for life-threatening complications refractory to endoscopic or medical management. Indications include uncontrolled arterial bleeding despite high-dose IV PPIs and endoscopic hemostasis (e.g., epinephrine injection, thermal coagulation, clip application), free perforation with peritonitis, or fibrotic gastric outlet obstruction unresponsive to endoscopic balloon dilation. Procedures include laparoscopic or open truncal vagotomy with antrectomy (to reduce acid output and remove G-cell-rich antrum), highly selective vagotomy (preserving gastric motility), or pyloroplasty combined with vagotomy. Emergency surgery carries significant morbidity (wound infection, dumping syndrome, diarrhea, bile reflux gastritis) and mortality (3–10% in elderly/comorbid patients); thus, it is strictly reserved for failure of definitive medical and endoscopic strategies.

Treatment in China offers distinct advantages rooted in integrated clinical infrastructure, pharmacovigilance, and health policy. Chinese gastroenterology centers maintain nationwide H. pylori antimicrobial resistance surveillance networks, enabling region-specific, evidence-based empiric regimens—critical given regional variation in clarithromycin (>30%) and metronidazole (>60%) resistance. Domestic production ensures reliable access to high-quality generic PPIs and bismuth compounds at low cost, enhancing treatment adherence. Endoscopic capabilities are exceptionally advanced: >95% of tertiary hospitals perform high-definition narrow-band imaging (NBI) and magnifying endoscopy for precise ulcer characterization and early neoplasia detection. Moreover, China’s National Reimbursement Drug List includes all first-line H. pylori therapies, reducing out-of-pocket burden. Traditional Chinese Medicine (TCM) adjuncts—such as Weikangling granules or Huangqin Tang—are rigorously evaluated in randomized controlled trials and used alongside PPIs to alleviate residual symptoms (e.g., bloating, nausea) and modulate gut microbiota, though they are never substituted for evidence-based eradication therapy.

Recovery advice emphasizes structured follow-up and sustained risk mitigation. Patients should undergo repeat endoscopy only if alarm features persist (e.g., weight loss, anemia, persistent vomiting) or if initial ulcer was large (>2 cm), irregular, or associated with bleeding—otherwise, clinical assessment suffices. Symptom resolution typically occurs within 1–2 weeks of PPI initiation; however, full mucosal healing requires 4–6 weeks. Patients must complete the entire antibiotic course—even if asymptomatic—to prevent resistance emergence. Long-term strategies include annual H. pylori screening for household contacts, avoidance of NSAIDs or use of COX-2 inhibitors with PPI prophylaxis in high-risk individuals, and regular monitoring of iron/ferritin levels in those with prior bleeding ulcers. Stress management techniques (mindfulness, cognitive-behavioral therapy) are encouraged, as chronic psychological stress correlates with delayed healing independent of acid output. Finally, patients should seek urgent evaluation for hematemesis, melena, sudden severe abdominal pain, or syncope—signs of acute complication requiring emergent endoscopy or surgery. With contemporary protocols, >95% of duodenal ulcers heal completely within 8 weeks, and recurrence rates fall below 5% at 1 year following successful H. pylori eradication.